Education
About Us
Working with TipRanks
Follow Us
BioNTech SE (BNTX)
NASDAQ:BNTX
Top Page
BioNTech SE
(NASDAQ:BNTX)
55Neutral
Positive Factors
Financial Performance
BioNTech remains a promising opportunity based on its substantial war chest, burgeoning pipeline, and plethora of upcoming data releases.
Oncology Pipeline
BioNTech's combination strategy yields promising results, with BNT327 plus ADCs showing superior anti-tumor effects preclinically versus each drug alone.
Strategic Developments
The company's balance sheet remains strong as they advance pivotal studies for BNT327 and move closer to a first commercial approval in oncology.
Negative Factors
COVID Business Uncertainty
There is uncertainty on the COVID business, with a need for further clarification on future approvals that could impact future COVID revenues, particularly in the US.
Regulatory Challenges
The current regulatory environment in the U.S. could produce significant headwinds for COVID-19 vaccine sales.
Revenue Performance
The company reported 1Q25 revenues of €183 M, which was 24% lower than the LP estimate and 7% lower than the Visible Alpha consensus.
BioNTech SE (BNTX) vs. S&P 500 (SPY)
Market Cap
$22.30B
Dividend YieldN/A
Average Volume (3M)1.32M
Price to Earnings (P/E)―
Beta (1Y)0.93
Revenue Growth0.58%
EPS Growth-764.64%
CountryUS
Employees6,772
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.94
Shares Outstanding240,392,620
10 Day Avg. Volume939,314
30 Day Avg. Volume1,315,758
Financial Highlights & Ratios
PEG Ratio0.79
Price to Book (P/B)1.09
Price to Sales (P/S)0.00
P/FCF Ratio-100.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$139.81Price Target Upside50.71% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
BioNTech SE Business Overview & Revenue Model
Company DescriptionBioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.
How the Company Makes MoneyBioNTech SE generates revenue through the development and commercialization of its mRNA-based therapies and vaccines. A significant portion of its income is derived from its collaboration with Pfizer, particularly from the sales of the COVID-19 vaccine, which has been distributed globally. The company also engages in strategic partnerships and licensing agreements with other pharmaceutical firms to enhance its development pipeline and expand its market reach. Additionally, BioNTech earns revenue through research grants and milestone payments associated with the progress of its clinical trials and product developments.
BioNTech SE Financial Statement Overview
Summary
BioNTech SE's financial performance shows mixed results. While the balance sheet is strong with a low debt-to-equity ratio and high equity ratio, income and cash flow metrics have been volatile. Recent revenue and profit margin declines, combined with fluctuating cash flows, indicate potential areas for improvement.Income Statement
BioNTech SE has experienced significant volatility in its revenue and profitability margins. The gross profit margin has generally been strong, averaging 80% during peak years, but has recently decreased. Net profit margin has also shown volatility, with recent negative figures after previous years of profitability. The revenue growth rate has been inconsistent, with a notable decline in recent years following a peak period.65
Positive
Balance Sheet
The balance sheet of BioNTech SE is robust, with a strong equity ratio averaging around 85% over the years, indicating solid financial stability. The company has maintained a low debt-to-equity ratio, reflecting prudent financial management. However, the return on equity has been volatile due to fluctuating net income, indicating potential concerns in sustained profitability.75
Positive
Cash Flow
BioNTech SE's cash flow statement reveals fluctuating free cash flow, with recent negative figures following a period of strong positive cash flow. The operating cash flow to net income ratio has also varied significantly, pointing to inconsistencies in cash generation relative to reported profits. This variability poses a risk to cash flow stability.60
Neutral
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 2.75B | 3.82B | 17.31B | 18.98B | 482.32M | Gross Profit |
| 2.21B | 3.22B | 12.78B | 15.12B | -222.04M | EBIT |
| -1.31B | 690.40M | 12.64B | 15.28B | -82.42M | EBITDA |
| -367.10M | 1.09B | 12.86B | 15.73B | -97.89M | Net Income Common Stockholders |
| -665.30M | 930.30M | 9.43B | 10.29B | 15.20M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 16.78B | 16.55B | 14.06B | 2.07B | 1.35B | Total Assets |
| 22.53B | 23.01B | 23.28B | 15.83B | 2.32B | Total Debt |
| 254.20M | 219.10M | 212.20M | 301.50M | 240.19M | Net Debt |
| -9.51B | -11.44B | -13.66B | -1.39B | -970.02M | Total Liabilities |
| 3.12B | 2.76B | 3.22B | 3.94B | 946.77M | Stockholders Equity |
| 19.41B | 20.25B | 20.06B | 11.89B | 1.37B |
| Cash Flow | Free Cash Flow | |||
| -244.60M | 4.67B | 13.21B | 735.70M | -98.92M | Operating Cash Flow |
| 207.70M | 5.37B | 13.58B | 889.70M | -13.47M | Investing Cash Flow |
| -2.08B | -6.95B | -35.30M | -566.10M | -144.85M | Financing Cash Flow |
| -45.90M | -778.60M | -1.42B | 94.20M | 894.73M |
BioNTech SE Technical Analysis
Neutral
92.77
Price Trends
97.85
Negative
107.25
Negative
106.93
Negative
Market Momentum
-1.81
Positive
49.84
Neutral
42.48
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNTX, the sentiment is Neutral. The current price of 92.77 is below the 20-day moving average (MA) of 100.23, below the 50-day MA of 97.85, and below the 200-day MA of 106.93, indicating a bearish trend. The MACD of -1.81 indicates Positive momentum. The RSI at 49.84 is Neutral, neither overbought nor oversold. The STOCH value of 42.48 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BNTX.
BioNTech SE Risk Analysis
BioNTech SE disclosed 1 risk factors in its most recent earnings report. BioNTech SE reported the most risks in the “Legal & Regulatory” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNTech SE Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | $12.23B | 11.33 | 22.69% | ― | 25.11% | 46.46% | |
69 Neutral | $34.42B | 40.72 | 17.33% | ― | 78.01% | ― | |
62 Neutral | $37.20B | ― | -414.62% | ― | 17.21% | 21.16% | |
55 Neutral | $22.30B | ― | -3.87% | ― | 0.58% | -764.64% | |
54 Neutral | $3.47B | ― | -51.57% | ― | 730.42% | 31.63% | |
52 Neutral | $5.15B | 3.02 | -44.64% | 2.83% | 16.44% | -0.47% | |
43 Neutral | $9.61B | ― | -29.34% | ― | -38.25% | 44.29% |
* Healthcare Sector Average
Performance Comparison
BNTX
BioNTech SE
97.80
5.33
5.76%
ALNY
Alnylam Pharma
291.86
141.62
94.26%
ARGX
Argenx Se
578.10
216.52
59.88%
GMAB
Genmab
20.18
-9.51
-32.03%
MRNA
Moderna
26.39
-114.62
-81.29%
SWTX
Springworks Therapeutics
46.27
3.81
8.97%
BioNTech SE Earnings Call Summary
Earnings Call Date:May 05, 2025
(Q1-2025)
| % Change Since: -11.60%|
Next Earnings Date:Aug 04, 2025
Earnings Call Sentiment Neutral
The earnings call reflects a company that is making significant progress in its oncology programs and maintaining a strong financial position, despite experiencing decreased revenue and a higher net loss. The strategic investments in developing new therapies and preparing for future product launches are promising, but the financial losses and settlement expenses are notable challenges.Q1-2025 Updates
Positive Updates
Advancements in Oncology Programs
BioNTech presented new clinical data for their bispecific immunomodulator BNT327 and mRNA cancer immunotherapies, showing potential to establish new standards of care in oncology. They are advancing towards commercialization with the first BLA submission for BNT323 planned by the end of 2025.
COVID-19 Vaccine Developments
BioNTech is preparing for a variant-adapted COVID-19 vaccine rollout and maintains a strong financial position to support these developments.
Strong Financial Position
Despite a net loss, BioNTech ended the quarter with €15.9 billion in total cash plus security investments, indicating robust financial health.
Negative Updates
Decreased Revenue and Increased Net Loss
BioNTech reported total revenues of approximately €183 million for Q1 2025, a slight decrease from €188 million in Q1 2024. The net loss for the first quarter of 2025 was €416 million, compared to a net loss of €315 million in the prior-year period.
High R&D and Settlement Costs
R&D expenses increased to €526 million, driven by late-stage clinical studies. Additionally, BioNTech faced significant settlement costs with NIH and the University of Pennsylvania, totaling approximately US$1.2 billion.
Company Guidance
In BioNTech's first quarter 2025 earnings call, the company provided guidance on several key metrics. They reported total revenues of approximately €183 million for the quarter, primarily from COVID-19 vaccine sales, compared to €188 million in the first quarter of 2024, reflecting expected seasonality. BioNTech's research and development expenses reached €526 million, up from €508 million in the prior-year period, driven by the advancement of late-stage clinical studies, including those for BNT327. Selling, general, and administrative expenses were €121 million, down from €133 million due to reduced external services. The company recorded a net loss of €416 million, compared to a €315 million loss in the same period last year, with a basic and diluted loss per share of €1.73 versus €1.31 previously. BioNTech ended the quarter with a strong cash position of €15.9 billion, despite significant outflows related to acquisitions and settlements. For the full year, BioNTech reaffirmed its 2025 financial guidance, projecting revenues between €1.7 billion and €2.2 billion, R&D expenses from €2.6 billion to €2.8 billion, SG&A expenses between €650 million and €750 million, and capital expenditures ranging from €250 million to €350 million.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.